Skip to main
ABCL

AbCellera Biologics (ABCL) Stock Forecast & Price Target

AbCellera Biologics (ABCL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AbCellera Biologics is a growing clinical-stage biotechnology company with a diverse pipeline of potential antibody medicines. The recent development agreement with Jazz Pharmaceuticals, along with the company's strong partnerships and proprietary technology platform, position it for potential future success. While the stock may face investment risks, such as regulatory hurdles and competition, the positive outlook on the company's potential for revenue growth and profitability lead to a Buy rating and a price target of $11 based on a valuation metric of 30x estimated revenues in 2027E.

Bears say

AbCellera Biologics is a clinical-stage biotechnology company with a growing pipeline of programs in early-stage development, leading to lower revenue generation and potential for failure in later trials. With a large number of external programs and a high concentration in early phases, AbCellera's financials may also be impacted in the short term due to deferred upfront payments from recent collaborations. Additionally, given the inherent risks of investing in early-stage biotech companies, AbCellera may be a risky investment.

AbCellera Biologics (ABCL) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbCellera Biologics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbCellera Biologics (ABCL) Forecast

Analysts have given AbCellera Biologics (ABCL) a Buy based on their latest research and market trends.

According to 6 analysts, AbCellera Biologics (ABCL) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbCellera Biologics (ABCL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.